TET1 and melanoma: Though TET1 mutations were observed across a wide range of different cancers, TET1 mutations were most strongly associated with improved responses to ICI-based immunotherapy in colorectal and melanoma patients, and in the case of colorectal cancer, exceeded the predictive value of TMB.